CRGX · Cargo Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | $7.51M | $30.64M | - | $35.93M | $37.46M | $30.50M | - | $22.23M |
| SG&A | $8.29M | $11.51M | - | $11.18M | $11.86M | $10.30M | - | $1.58M |
| Total Operating Expenses | $52.90M | $88.42M | - | $47.11M | $17.80M | $40.81M | - | $28.71M |
| D&A | $40.0K | $672.0K | - | $700.0K | $600.0K | $553.0K | - | $100.0K |
| Operating Income | ($52.90M) | ($88.42M) | - | ($47.11M) | ($17.80M) | ($40.81M) | - | ($10.05M) |
| Interest Expense | - | - | - | - | - | $1.60M | - | $1.46M |
| Income Tax | - | - | - | - | - | - | - | - |
| Net Income | ($49.94M) | ($84.50M) | - | ($41.91M) | ($44.35M) | ($35.81M) | - | ($12.29M) |
| EPS - Basic | ($1.04) | ($1.77) | - | ($0.88) | ($26.56) | ($0.87) | - | ($47.37) |
| EPS - Diluted | ($1.04) | ($1.77) | - | ($0.88) | ($1.02) | ($0.87) | - | ($47.37) |
Balance Sheet
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $107.75M | $61.77M | $64.38M | $71.18M | $153.58M | $58.77M | $405.73M | $60.34M |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - |
| Accounts Payable | $8.67M | $4.23M | $2.44M | $5.37M | $7.01M | $7.17M | $5.01M | $7.43M |
| Current Assets | $258.61M | $324.81M | $345.01M | $410.02M | $448.10M | $379.95M | $409.48M | $63.42M |
| Total Assets | $258.61M | $361.96M | $414.05M | $450.96M | $490.01M | $422.43M | $453.04M | $10.24M |
| Current Liabilities | $20.91M | $51.55M | $25.03M | $21.64M | $26.42M | $22.65M | $21.16M | $44.14M |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $20.91M | $79.50M | $53.83M | $50.08M | $53.91M | $49.22M | $47.65M | $45.48M |
| Stockholders' Equity | $237.70M | $282.46M | $360.23M | $400.88M | $436.10M | $373.21M | $405.39M | ($74.98M) |
| Retained Earnings | ($447.08M) | ($397.15M) | ($312.65M) | ($267.21M) | ($225.31M) | ($180.96M) | ($145.15M) | ($113.07M) |
Cash Flow
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($37.69M) | - | - | - | ($30.15M) | - | - |
| Investing Cash Flow | - | $35.04M | - | - | - | ($293.96M) | - | - |
| Financing Cash Flow | - | $38.0K | - | - | - | ($104.0K) | - | - |
| CapEx | - | $1.29M | - | - | - | $1.29M | - | - |
| Free Cash Flow | - | ($38.98M) | - | - | - | ($31.43M) | - | - |
Ratios
| Metric | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - |
| FCF / Net income | - | 0.46 | - | - | - | 0.88 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | -19.3% | -23.3% | - | -9.3% | -9.1% | -8.5% | - | -119.9% |
| Return on equity | -21.0% | -29.9% | - | -10.5% | -10.2% | -9.6% | - | 16.4% |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 12.37 | 6.30 | 13.79 | 18.95 | 16.96 | 16.78 | 19.35 | 1.44 |
| Quick ratio | 12.37 | 6.30 | 13.79 | 18.95 | 16.96 | 16.78 | 19.35 | 1.44 |
| Cash ratio | 5.15 | 1.20 | 2.57 | 3.29 | 5.81 | 2.59 | 19.17 | 1.37 |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -25.4x | - | -6.9x |
| Equity multiplier | 1.09 | 1.28 | 1.15 | 1.12 | 1.12 | 1.13 | 1.12 | -0.14 |
| Liabilities / Assets | 0.08 | 0.22 | 0.13 | 0.11 | 0.11 | 0.12 | 0.11 | 4.44 |
| Efficiency | ||||||||
| Asset turnover | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -197.3% | -116.7% | - | -368.8% | - | - | - | - |
| Net income growth (YoY) | -12.6% | -136.0% | - | -241.1% | - | - | - | - |
| EPS growth (YoY) | -2.0% | -103.4% | - | 98.1% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | -24.0% | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -45.5% | -24.3% | -11.1% | - | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing CARGO Therapeutics against the 5 most active filers in the same SIC group.